Sponsored, no-charge genetic testing for hypophosphatemia for patients in Canada
Ultragenyx Canada Inc. and Invitae have partnered to offer sponsored genetic testing to patients aged 6 months and older who have been clinically diagnosed with X-linked hypophosphatemia (XLH) and need confirmatory testing.
Certain hypophosphatemia disorders have an underlying genetic cause. An accurate diagnosis may have an impact on clinical management of the condition including customizing care to a patient's specific needs and connecting patients.
Program eligibility
The patient must be aged 6 months or older and meet one of the following criteria below:
-
Has completed the UltraCare® Enrolment Form for XLH; or
-
Has a previous diagnosis related to hypophosphatemia; or
-
Has a family member with a confirmed XLH diagnosis; or
-
Exhibit TWO or more of the following clinical signs and/or symptoms:
|
|
|
About XLH
-
XLH, the most common form of genetic hypophosphatemia, is caused by mutations in the PHEX gene.1
-
XLH is an X-linked dominant disorder, meaning that the genetic variant (located on the X chromosome) only needs to exist in one copy of a patient’s genes to cause the disorder.
-
Women with XLH have a 50% chance of passing the disorder on to each of their children, regardless of gender, while men with XLH will pass the disorder on to all of their daughters and none of their sons.2
-
XLH is also known by a number of other names including X-linked hypophosphatemic rickets, hereditary hypophophatemic rickets, familial hypophosphatemic rickets, vitamin D-resistant rickets (VDRR), vitamin D-resistant osteomalacia, X-linked vitamin D-resistant rickets, hypophosphatemic rickets, hypophosphatemic vitamin D-resistant rickets (HPDR), X-linked rickets (XLR), genetic rickets, and familial hypophosphatemia.1-5
-
An accurate diagnosis of genetic hypophosphatemia may help to inform treatment decisions.
Genetic testing with Invitae
The Hypophosphatemia program offers testing with the Invitae Hypophosphatemia Panel
The Invitae Hypophosphatemia Panel includes genes known to be associated with hypophosphatemia: ALPL, CLCN5, CTNS, CYP2R1, CYP27B1, DMP1, ENPP1, FAH, FAM20C, FGF23, FGFR1, GNAS, OCRL, PHEX, SLC34A1, SLC34A3 and VDR. Once Invitae receives the sample, your results will be available in 10 to 21 calendar days on average.
VIEW PANELNext steps and additional services
Family variant testing for familial insights
If a positive result is identified, testing for your patient’s family members is available.
Simply follow the ordering instructions, selecting only the gene(s) you are interested in testing for the family member. The partner code will automatically be added with the order.
Support every step of the way
Client services
Available to answer your questions or help you through the testing process.
CONTACTAbout Invitae
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve health care for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com.
About Ultragenyx Canada Inc.
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at ultragenyx.com.
Disclaimer
While Ultragenyx Canada Inc. provides financial support for this program, the genetic testing and counseling services are performed by independent third parties. Health care professionals must confirm that patients meet certain criteria to use the program and shall not seek reimbursement for the testing or services provided under this program from any third party, including but not limited to federal health care programs. Ultragenyx receives de-identified patient data from this program, but at no time does Ultragenyx receive patient identifiable information. Ultragenyx receives contact information for healthc are professionals who use this program. Genetic testing services are available in Canada only. Health care professionals who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any Ultragenyx product.
References
- X-linked hypophosphatemia. Genetic and Rare Diseases Information Center (GARD) website. https://rarediseases.info.nih.gov/diseases/12943/x-linked-hypophosphatemia. Updated 2018. Accessed January 3, 2019.
- Ruppe MD. X-linked hypophosphatemia. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews. [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
- Hereditary hyphosphatemic rickets. Genetics Home Reference website. https://ghr.nlm.nih.gov/condition/hereditary-hypophosphatemic-rickets. Updated January 2, 2019. Accessed January 3, 2019.
- What is XLH? XLH Network website. https://xlhnetwork.org/what-is-xlh. Updated August 13, 2017. Accessed January 3, 2019.
- Wang M, Cao X, Cao B. Hypophosphatemic vitamin D-resistant osteomalacia: a case report. Exp Ther Med. 2013;6(3):791-5.
